A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
about
Vaccines against malariaA review of malaria vaccine clinical projects based on the WHO rainbow tableDNA vaccines: designing strategies against parasitic infectionsA randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adultsThe evolution of poxvirus vaccinesImmune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceInduction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccineProcess development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparumEnhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraProtective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirsSafety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsA DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.Progress in DNA-based heterologous prime-boost immunization strategies for malaria.MVA as a vector for vaccines against HIV-1.Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of MiceFowlpox virus as a recombinant vaccine vector for use in mammals and poultry.Building better T-cell-inducing malaria vaccines.DNA vaccines against tropical parasitic diseases.Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1Viral vector vaccines make memory T cells against malaria.Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response.Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection.High-capacity adenoviral vectors circumvent the limitations of ΔE1 and ΔE1/ΔE3 adenovirus vectors to induce multispecific transgene product-directed CD8 T-cell responses.O-GlcNAc modification of the anti-malarial vaccine candidate PfAMA1: in silico-defined structural changes and potential to generate a better vaccine.
P2860
Q17485685-08CCAC02-6636-4321-9C10-EF251174B523Q21034112-F348BCAE-0BD0-451D-A0D7-630D22709190Q24801950-EA8F8012-99C0-40BC-A1E4-5DDDEBF91025Q24804936-2C00707E-294E-44BC-90B6-162E55FD6E4DQ26995905-E35A0624-82ED-41CA-A7DE-B11264A15106Q28748570-902C8231-D975-4FA3-B827-FCD987C10073Q33214292-9D7A9E08-9130-45F8-8026-4D2048F1064CQ33769381-ACD8175C-E952-4913-B8E7-67B281134EEDQ33935092-4F80CC19-B25B-4C25-8948-6E013F50FCCDQ34422345-30E4489E-A8E2-4B6A-94A0-1230429FB8C5Q34634002-D59E1F75-40DC-41A5-B88A-FFFA08C209D5Q35073970-9FCA05CD-36E4-42F3-BD8D-B53DB6ABE330Q35367108-DCBE5DF3-1BBB-43E4-9C26-6E3669C11086Q35826388-F4C9E560-00E0-452B-ACC7-5AE2E0B55E53Q35851793-8A3129D2-460C-4A40-A844-43268E27580AQ35867348-431E11C5-A82F-4501-91E4-0D4BE567EBD3Q36066251-98318AD7-8B43-4AE1-ACBC-D62027A30AA4Q36122648-8EA5EC54-3F43-4F8D-BFE5-7DBDA8D003A8Q36238733-3B11244F-CA47-40F8-A428-1C05F3BA7C84Q36383811-2EEA5BC2-0434-48AB-B26D-C78FFECA78AFQ36539553-82B1BF64-04AB-4A1D-B7BE-C41B161D2FF6Q36802741-F9A51BA2-D19E-4CC8-BA46-E4D85623E488Q37001511-CB26938C-71CF-4111-B9E7-17964F8E0253Q37023939-949D3FDD-AD0B-4188-AE15-44FE69B7D182Q38786910-0ACC3822-BAD5-457D-8C18-D62451F7B04CQ40545644-921752BE-64AE-4F4C-AE7D-0C3E544C117AQ40752357-96FB1C1B-A0A7-4266-81CE-FAF86884DB46Q44991675-9E8B6275-9C6A-4B66-94AA-FDEF69135F84Q45875102-191E6495-A7C6-44CD-B4FD-EA3C48DCC13AQ47993122-0208008A-9F27-45BA-8DF5-A09E57BE0E33
P2860
A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@ast
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@en
type
label
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@ast
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@en
prefLabel
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@ast
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@en
P2093
P2860
P356
P1476
A Plasmodium falciparum candid ...... ded by recombinant poxviruses.
@en
P2093
Anne C Moore
Eric G Sheu
Eric Prieur
Joerg Schneider
Kathryn J H Robson
Nilu Goonetilleke
P2860
P304
P356
10.1073/PNAS.0307158101
P407
P577
2003-12-23T00:00:00Z